Population Pharmacokinetic –Pharmacodynamic Relationships of Sarilumab Using Disease Activity Score 28-Joint C-Reactive Protein and Absolute Neutrophil Counts in Patients with Rheumatoid Arthritis

ConclusionThe PopPK/PD models showed numerically greater reductions in DAS28-CRP and ANC with sarilumab 200  mg every 2 weeks than with 150 mg every 2 weeks. There was no clinically meaningful influence of investigated covariates. These data contribute to the totality of evidence that supports a sarilumab subcutaneous starting dose of 200 mg every 2 weeks, with a subsequent reduction to 150 mg ever y 2 weeks in the event of laboratory abnormalities such as neutropenia.
Source: Clinical Pharmacokinetics - Category: Drugs & Pharmacology Source Type: research